The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer

Clinica Chimica Acta

Volumn 436, Issue , 2014, Pages 243-248

  Wang, Hongchun ^a   Huang, Xiangnan ^a   Zhang, Jingru ^a   Shao, Na ^a   Chen, L ong ^a   Ma, Daoxin ^a   Ji, Chunyan ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Angiogenesis; Dll4 Notch; Ovarian cancer; VEGF

Indexed keywords

CD34 ANTIGEN; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR; PROTEIN DLL4; TUMOR PROMOTER; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; DELTA PROTEIN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; RECEPTORS, NOTCH; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

ADULT; AGED; ARTICLE; ASCITES; CANCER DIAGNOSIS; CAPILLARY DENSITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REGULATORY MECHANISM; AGED, 80 AND OVER; BLOOD SUPPLY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METABOLISM; MICROVESSELS; MIDDLE AGED; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICROVESSELS; MIDDLE AGED; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84903434928     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.06.005     Document Type: Article

References (47)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics,2007. CA Cancer J Clin 2007, 57:43-66.
2. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. Partridge E.E., Barnes M.N. Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J Clin 1999, 49:297-320.
4. Collinson F., Jayson G. New therapeutic agents in ovarian cancer. Curr Opin Obstet Gynecol 2009, 21:44-53.
5. Spannuth W.A., Sood A.K., Coleman R.L. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008, 5:194-204.
6. Buckanovich R.J., Sasaroli D., O'Brien-Jenkins A., et al. Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 2007, 25:852-861.
7. Bellati F., Napoletano C., Gasparri M.L., et al. Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms. Crit Rev Oncol Hematol Jul 2012, 83:35-46.
8. Hurt J.D., Richardson D.L., Seamon L.G., et al. Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer. Gynecol Oncol 2009, 115:396-400.
9. Spratlin J.L., Cohen R.B., Eadens M., et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010, 28:780-787.
10. Rehman A.O., Wang C.Y. Notch signaling in the regulation of tumor angiogenesis. Trends Cell Biol 2006, 16:293-300.
11. Liu Z.J., Shirakawa T., Li Y., et al. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 2003, 23:14-25.
12. Hu W., Lu C., Dong H.H., et al. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer. Cancer Res 2011, 71:6030-6039.
13. Rubatt J.M., Darcy K.M., Hutson A., et al. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: a Gynecologic Oncology Group study. Gynecol Oncol 2009, 112:469-474.
14. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995, 36:169-180.
15. Yancopoulos G.D., Davis S., Gale N.W., et al. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248.
16. Nagy J.A., Dvorak A.M., Dvorak H.F. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2007, 2:251-275.
17. Ferrara N., Gerber H.P., Lecouter J., et al. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
18. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003, 9:653-660.
19. Jain R.K. Molecular regulation of vessel maturation. Nat Med 2003, 9:685-693.
20. Clauss M., Weich H., Breier G., et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996, 271:17629-17634.
21. Paley P.J., Staskus K.A., Gebhard K., et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997, 80:98-106.
22. Kassim S.K., El-Salahy E.M., Fayed S.T., et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 2004, 37:363-369.
23. Cooper B.C., Ritchie J.M., Broghammer C.L., et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res 2002, 8:3193-3197.
24. Li L., Wang L., Zhang W., et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res 2004, 24:1973-1979.
25. Hefler L.A., Zeillinger R., Grimm C., et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol 2006, 103:512-517.
26. Kuemmel S., Thomas A., Landt S., et al. Circulating vascular endothelial growth factors and their soluble receptors in pre-invasive, invasive and recurrent cervical cancer. Anticancer Res 2009, 29:641-645.
27. Randall L.M., Monk B.J., Darcy K.M., et al. Markers of angiogenesis in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2009, 112:583-589.
28. Chen H., Ye D., Xie X., Chen B., Lu W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol 2004, 94:630-635.
29. Frumovitz M., Sood A.K. Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol Oncol 2007, 104:768-778.
30. Zhang A., Meng L., Wang Q., et al. Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2. Oncol Rep 2006, 15:831-836.
31. Li J.L., Harris A.L. Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. Front Biosci (Landmark Ed) 2009, 14:3094-3110.
32. Thurston G., Kitajewski J. VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis. Br J Cancer 2008, 99:1204-1209.
33. Stenzel D., Franco C.A., Estrach S., et al. Endothelial basement membrane limits tip cell formation by inducing Dll4/Notch signalling in vivo. EMBO Rep 2011, 12:1135-1143.
34. Takeshita K., Satoh M., Ii M., et al. Critical role of endothelial Notch1 signaling in postnatal angiogenesis. Circ Res 2007, 100:70-78.
35. Iso T., Hamamori Y., Kedes L. Notch signaling in vascular development. Arterioscler Thromb Vasc Biol 2003, 23:543-553.
36. Dufraine J., Funahashi Y., Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008, 27:5132-5137.
37. Alitalo K., Tammela T., Petrova T.V. Lymphangiogenesis in development and human disease. Nature 2005, 438:946-953.
38. Nicolas M., Wolfer A., Raj K., et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003, 33:416-421.
39. Hopfer O., Zwahlen D., Fey M.F., et al. The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer 2005, 93:709-718.
40. Patel N.S., Li J.L., Generali D., et al. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 2005, 65:8690-8697.
41. Hainaud P., Contreres J.O., Villemain A., et al. The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res 2006, 66:8501-8510.
42. Ridgway J., Zhang G., Wu Y., et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006, 444:1083-1087.
43. Hellstrom M., Phng L.K., Hofmann J.J., et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007, 445:776-7780.
44. Lobov I.B., Renard R.A., Papadopoulos N., et al. Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A 2007, 104:3219-3224.
45. Suchting S., Freitas C., le Noble F., et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci U S A 2007, 104:3225-3230.
46. Taylor K.L., Henderson A.M., Hughes C.C. Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/KDR expression. Microvasc Res 2002, 64:372-383.
47. Harrington L.S., Sainson R.C., Williams C.K., et al. Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc Res 2008, 75:144-154.